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Summary
Comprehensive guidelines for treatment of latent tuberculosis infection (LTBI) among persons living in the United States were 
last published in 2000 (American Thoracic Society. CDC targeted tuberculin testing and treatment of latent tuberculosis 
infection. Am J Respir Crit Care Med 2000;161:S221–47). Since then, several new regimens have been evaluated in clinical 
trials. To update previous guidelines, the National Tuberculosis Controllers Association (NTCA) and CDC convened a committee to 
conduct a systematic literature review and make new recommendations for the most effective and least toxic regimens for treatment 
of LTBI among persons who live in the United States.  
The systematic literature review included clinical trials of regimens to treat LTBI. Quality of evidence (high, moderate, low, or 
very low) from clinical trial comparisons was appraised using the Grading of Recommendations Assessment, Development, and 
Evaluation (GRADE) criteria. In addition, a network meta-analysis evaluated regimens that had not been compared directly 
in clinical trials. The effectiveness outcome was tuberculosis disease; the toxicity outcome was hepatotoxicity. Strong GRADE 
recommendations required at least moderate evidence of effectiveness and that the desirable consequences outweighed the undesirable 
consequences in the majority of patients. Conditional GRADE recommendations were made when determination of whether 
desirable consequences outweighed undesirable consequences was uncertain (e.g., with low-quality evidence).
These updated 2020 LTBI treatment guidelines include the NTCA- and CDC-recommended treatment regimens that comprise 
three preferred rifamycin-based regimens and two alternative monotherapy regimens with daily isoniazid. All recommended treatment 
regimens are intended for persons infected with Mycobacterium tuberculosis that is presumed to be susceptible to isoniazid or 
rifampin. These updated guidelines do not apply when evidence is available that the infecting M. tuberculosis strain is resistant 
to both isoniazid and rifampin; recommendations for treating contacts exposed to multidrug-resistant tuberculosis were published 
in 2019 (Nahid P, Mase SR Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA 
clinical practice guideline. Am J Respir Crit Care Med 2019;200:e93–e142). The three rifamycin-based preferred regimens 
are 3 months of once-weekly isoniazid plus rifapentine, 4 months of daily rifampin, or 3 months of daily isoniazid plus rifampin. 
Prescribing providers or pharmacists who are unfamiliar with rifampin and rifapentine might confuse the two drugs. They are 
not interchangeable, and caution should be taken to ensure that patients receive the correct medication for the intended regimen. 
Preference for these rifamycin-based regimens was made on the basis of effectiveness, safety, and high treatment completion rates. 
The two alternative treatment regimens are daily isoniazid for 6 or 9 months; isoniazid monotherapy is efficacious but has higher 
toxicity risk and lower treatment completion rates than shorter rifamycin-based regimens.
In summary, short-course (3- to 4-month) rifamycin-based treatment regimens are preferred over longer-course (6–9 month) isoniazid 
monotherapy for treatment of LTBI. These updated guidelines can be used by clinicians, public health officials, policymakers, health 
care organizations, and other state and local stakeholders who might need to adapt them to fit individual clinical circumstances.
Corresponding author: Carla A. Winston, National Center for 
HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of 
Tuberculosis Elimination, CDC. Telephone: 404-718-8008; E-mail: 
CWinston@cdc.gov.
Introduction
One fourth of the global population (approximately 2 billion 
persons) is estimated to be infected with Mycobacterium 
tuberculosis (1), including approximately 13 million in the 
United States (2). Most infected persons are asymptomatic 
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and classified as having latent tuberculosis infection (LTBI). 
If untreated, approximately 5%–10% of persons with LTBI 
progress to tuberculosis (TB) disease during their lifetime (3–5). 
Progression from untreated LTBI accounts for approximately 
80% of U.S. TB disease cases (6). Treatment of LTBI is effective 
in preventing progression to TB disease (7). The most recent 
comprehensive guidelines for treatment of LTBI in the United 
States were published in 2000 (8). In 2003, CDC and the 
American Thoracic Society recommended against use of the 
2-month regimen of rifampin plus pyrazinamide because of 
the risk for severe hepatotoxicity (9). Since then, several new 
regimens have been evaluated in clinical trials. To update the 
2000 and 2003 treatment guidelines, the National Tuberculosis 
Controllers Association (NTCA) and CDC convened a 
committee to conduct a systematic literature review of clinical 
trials for the treatment of LTBI. Grading of Recommendations 
Assessment, Development, and Evaluation (GRADE) criteria 
were applied to the evidence of effectiveness, a network meta-
analysis of selected evidence was performed, and the evidence 
was used to support 2020 LTBI treatment guidelines.
These updated 2020 LTBI treatment guidelines apply to 
persons with LTBI who live in the United States. In addition, 
these guidelines apply to persons infected with M. tuberculosis 
that is presumed to be susceptible to isoniazid or rifampin; 
they do not apply when evidence is available that the infecting 
M. tuberculosis strain is resistant to both isoniazid and rifampin. 
Local and state TB programs in the United States answer 
questions about diagnosing and treating persons with LTBI in 
their jurisdictions (http://www.tbcontrollers.org).
Methods
These updated guidelines were developed by NTCA and 
CDC. The LTBI treatment guidelines committee members, 
who are the authors of this report, were nominated on the basis 
of their expertise in treatment of LTBI. The committee had 
expertise in epidemiology, domestic and international TB control, 
clinical trials, and treatment of LTBI in adults and children. A 
methodologist with expertise in the GRADE approach served as 
a consultant to the guideline development committee.
Evidence Search
The committee determined that the following clinical 
question should be addressed in the updated guidelines: 
“Which regimens for treatment of latent tuberculosis infection 
have the greatest effectiveness and least toxicity?” The question 
was written in the population, intervention, comparator, 
outcomes (PICO) format, and then the outcomes were rated 
as critical, important, or not important. Comparison of 
regimen toxicities was limited to hepatotoxicity because this 
was the only toxicity that could be consistently compared 
across studies.
A systematic literature review was initiated in December 2017. 
Electronic databases including MEDLINE, Embase, CINAHL, 
ClinicalTrials.gov, the Cochrane Central Register of Controlled 
Trials (CENTRAL), and gray literature were searched for 
studies evaluating the effectiveness of LTBI treatment regimens. 
Search terms included “latent tuberculosis,” “latent TB,” 
“LTBI,” “Mycobacterium tuberculosis,” “tuberculosis infection” 
AND “isoniazid,” “rifampin,” “rifapentine,” or “pyrazinamide.” 
Articles were included if the study design was a randomized 
controlled trial and outcomes included prevention of TB 
disease and drug-related hepatotoxicity. Studies that included 
persons with suspected or confirmed TB disease were excluded 
from the review.
The initial search located a high-quality systematic review 
and meta-analysis published in August 2017 that examined 
the effectiveness of LTBI treatment regimens (10). The study 
authors were contacted and asked for access to the extracted 
data. Study characteristics, types of participants, interventions, 
the outcomes measured, and results were extracted from 
each study. If the data were amenable to pooling, effects 
were estimated via meta-analysis. For the meta-analyses, a 
random effects model was used unless otherwise specified, 
and effect estimates were reported as odds ratios. All statistical 
analyses were conducted using the “metafor” package in R, 
versions 3.4.3 (11). The Cochrane risk-of-bias tool was used 
to conduct a bias assessment (12). Analyses conducted in 2018 
included combined data from the studies in the previous review 
and articles identified during an updated search for studies 
published during June 2017–August 2018 (Figure) (13,14).
All treatment regimens were analyzed using a Bayesian 
network meta-analysis (NMA) approach, which allowed 
for indirect comparisons of treatment regimens when direct 
comparisons were not available. However, direct, pairwise 
meta-analysis was the preferred method; the results of the 
network analysis are presented in this report only if no direct 
comparisons were available. A full description of the network 
analysis method has been previously published (10,15). NMA 
allows for indirect comparisons of treatment regimens through 
inference from a network of evidence. For this analysis, 
WinBUGS software (version 1.4; Medical Research Council 
Biostatistics Unit of the University of Cambridge) was used 
to create the Bayesian network with posterior distributions on 
the basis of 20,000 samples after a burn-in period of 10,000 
iterations (15). Convergence was assessed by inspecting 
parameter chains and the Gelman–Rubin diagnostic (16). 
Summary statistics and 95% credible intervals were obtained 
from posterior distributions. Network inconsistency, which 
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FIGURE. Systematic literature review search process* for latent tuberculosis infection treatment regimens recommended by the National 
Tuberculosis Controllers Association and CDC, 2020
Deduplicated
(n = 2,648)
Excluded
(n = 2,535)
Not relevant
(n = 52) 
Ordered full text
(n = 113) 
LTBI treatment studies
(n = 61) 
Total included studies
(n = 63) 
Database  inception through May 2017
(n = 3,092) 
June 2017–August 2018
(n = 20)
Existing systematic review search Updated search
LTBI treatment studies
(n = 2) 
Ordered full text
(n = 3)  
Duplicates
(n = 0) 
Excluded
(n = 17)
Excluded,
no outcome of interest
(n = 1) 
Abbreviation: LTBI = latent tuberculosis infection.
* Existing systematic review search: the results from the 2017 analysis were published, citing all primary studies included in the analysis (Zenner D, Beer N, Harris RJ, 
Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med 2017;167:248–5). Updated 
search: analyses included combined data from the studies included in the previous review and articles identified during an updated search for studies published 
during June 2017–August 2018.
can arise if indirect comparisons conflict with direct pairwise 
estimates, was assessed by comparison with standard meta-
analysis and by using the omnibus test for consistency (17).
The overall quality of evidence was appraised using the 
GRADE approach, and GRADEpro software was used to 
develop evidence profiles that summarized the quality of 
evidence for each outcome (high, moderate, low, or very low) 
and the rationale for the quality of evidence appraisal (18). Head-
to-head comparisons of regimens evaluated in clinical trials were 
evaluated according to the populations studied: adults, children, 
HIV positive, and HIV negative. References for all of the studies 
included in the analyses are available (Supplementary Tables; 
https://stacks.cdc.gov/view/cdc/84235).
Development of Recommendations
The committee discussed evidence during face-to-face 
meetings and teleconferences. GRADE evidence tables were 
prioritized according to the regimens, comparisons, and study 
populations that were deemed most clinically relevant to the 
United States. If discrepancies between GRADE head-to-
head comparisons and network meta-analysis results were 
found, the committee prioritized the GRADE comparisons. 
Recommendations were formulated on the basis of the 
following considerations: the balance of desirable consequences 
of the intervention (benefits) and undesirable consequences 
(regimen complexity, adverse effects, and cost), the quality of 
evidence, patient values and preferences, and feasibility (19). 
The desirable and undesirable consequences considered by the 
committee included both those related to individuals and to 
overall public health.
A strong GRADE recommendation for a regimen was made 
if the panel concluded that the desirable consequences of the 
intervention outweighed the undesirable consequences, the 
majority of well-informed patients would choose the regimen, 
and the evidence was at least moderate quality (18,19). A 
conditional GRADE recommendation was made for a regimen 
when uncertainty existed regarding whether the desirable 
consequences outweighed the undesirable consequences 
(e.g., low-quality evidence for a critical outcome such that 
additional evidence could change key findings, hence the 
recommendation) (18,19). A conditional recommendation 
indicates that well-informed patients might make different 
choices regarding whether to choose the regimen (18,19).
The panel also prioritized recommended regimens as either 
preferred or alternative. Preferred regimens were defined as 
having excellent tolerability and efficacy, shorter treatment 
duration, and higher completion rates. Alternative regimens 
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were defined as having excellent efficacy but longer treatment 
duration and lower completion rates. The rationale for 
prioritizing the regimens was that treatment completion rates 
are higher with shorter regimens (20); if regimens have similar 
efficacy and safety, the shorter regimen is more effective because 
completion rates are higher.
Draft recommendations were publicly presented during the 
U.S. Advisory Council on the Elimination of Tuberculosis 
meeting on December 11, 2018, and at the NTCA meeting on 
April 23, 2019. The recommendations were positively received 
at both meetings, and no substantive changes were made to 
the recommendations thereafter.
Results
The GRADE evidence tables are provided (Table 1) 
(Supplementary Tables; https://stacks.cdc.gov/view/
cdc/84235). The Supplementary Tables contain all references; 
selected references are included in this report. In total, 
55 clinical trials evaluated effectiveness (7,13,14,21–74), 
and 31 trials evaluated toxicity (13,14,27,35–38,43–
46,49,51–53,55,61–66,68,71,72,75–82). Results of the 
2018 updated network meta-analysis are provided (Table 2); 
63 studies of 16 regimens were evaluated (7,13,14,21–82).
Summary of Evidence and 
Recommendations
The recommended treatment regimens include three 
preferred and two alternative treatment regimens (Tables 3 
and 4). Rifamycin-based regimens, including 3 months of 
once-weekly isoniazid plus rifapentine, 4 months of daily 
rifampin, and 3 months of daily isoniazid plus rifampin 
are the preferred recommended regimens because of their 
effectiveness, safety, and high treatment completion rates. 
Regimens of 6 or 9 months of daily isoniazid are alternative 
recommended regimens; although efficacious, they have 
higher toxicity risk and lower treatment completion rates, 
which decrease effectiveness. On the basis of the most recent 
comprehensive LTBI treatment guidelines in the United States, 
which were published in 2000 (8), 9 months of daily isoniazid 
was considered the standard comparator regimen to evaluate 
shorter-course regimens. Data on the effectiveness and toxicity 
of 9 months of daily isoniazid are provided, as are data on the 
other recommended regimens. A rifamycin-based regimen 
refers to treatment that includes either rifampin or rifapentine. 
Preferred Regimens
Three Months of Weekly Isoniazid Plus Rifapentine 
A regimen of 3 months of once-weekly isoniazid plus 
rifapentine is a preferred regimen that is strongly recommended 
for adults and children aged >2 years, including HIV-
positive persons (as drug interactions allow). This regimen, 
administered through directly observed therapy, had equivalent 
effectiveness and was not more toxic than the standard regimen 
of 9 months of daily isoniazid in adults and children aged 
>2 years (53,68,83). Treatment completion rates were higher 
with the 3-month regimen. In HIV-negative persons in a 
noninferiority study, 3 months of isoniazid and rifapentine 
was equivalent to and was associated with less hepatoxicity 
than 9 months of isoniazid, despite more discontinuation 
because of adverse effects (68). In HIV-positive persons, no 
significant difference was found in a comparison of isoniazid 
plus rifapentine for all outcomes with either 6 or 9 months 
of isoniazid (22,53). In a noninferiority study of 3 months 
of weekly isoniazid plus rifapentine, the completion rate by 
self-administered therapy was inferior to the rate with direct 
observation but noninferior in the prespecified subpopulation 
from the United States (84).
Potential disadvantages of this regimen include cost of 
medications that are greater than most alternatives, potential 
added costs if provided by directly observed therapy (with 
treatment completion being highest with directly observed 
therapy, although self-administered therapy is an approved 
option) (85), the need to take numerous pills simultaneously 
(10 pills once weekly compared with two or three pills daily 
for other regimens for most adults), and the association with 
a systemic drug reaction or influenza-like syndrome that can 
include syncope and hypotension. Severe events requiring 
hospitalization occurred in 0.1% of persons (68,86). The 
systemic drug reaction is self-limited and usually mild; no deaths 
have been reported. Potential drug interactions and acquired 
drug resistance if TB disease is not adequately excluded also are 
important considerations for all treatment regimens.
Four Months of Daily Rifampin
A regimen of 4 months of daily rifampin is a preferred treatment 
that is strongly recommended for HIV-negative adults and 
children of all ages. (No evidence is available for effectiveness 
in HIV-positive persons.) The effectiveness of this regimen was 
clinically equivalent to, and less toxic than, the standard regimen of 
9 months of daily isoniazid in adults and children (13,14,78,79). 
Four months of daily rifampin had noninferior effectiveness in 
preventing TB disease compared with 9 months of daily isoniazid, 
as well as a lower rate of treatment discontinuation because of 
Recommendations and Reports
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TABLE 1. Summary of GRADE evidence tables, by treatment regimen and study population*
Regimen
Population
No. of trials
Experimental regimen Comparator regimen Effectiveness Toxicity
3 mos isoniazid plus rifapentine given once weekly 9 mos isoniazid HIV-positive adults 1 1
3 mos isoniazid plus rifapentine given once weekly 9 mos isoniazid HIV-negative adults and children 1 1
3 mos isoniazid plus rifapentine given once weekly 9 mos isoniazid HIV-negative children 1 1
3 mos isoniazid plus rifapentine given once weekly 6 mos isoniazid HIV-positive adults 1 1
3 mos isoniazid plus rifampin given daily 9 mos isoniazid HIV-negative adults 1 1
3 mos isoniazid plus rifampin given daily 6 mos isoniazid HIV negative adults and children 3 2
3 mos isoniazid plus rifampin given daily 6 mos isoniazid HIV-positive adults 4 4
3 mos isoniazid plus rifampin given daily Placebo or no treatment HIV-positive adults 2 1
3 mos isoniazid plus rifampin given daily Placebo or no treatment HIV-negative adults and children 2 0
4 mos rifampin given daily 9 mos isoniazid HIV-negative adults 1 2
4 mos rifampin given daily 9 mos isoniazid HIV-negative children 1 1
4 mos rifampin given daily 6 mos isoniazid HIV-negative children 1 0
6 mos isoniazid given daily Placebo HIV-negative adults and children 4 2
6 mos isoniazid given daily Placebo or no treatment HIV-positive adults 5 3
9 mos isoniazid given daily No treatment HIV-negative adults and children 2 0
12 mos isoniazid given daily No treatment HIV-positive adults 2 0
12 mos isoniazid given daily Placebo HIV-positive adults and children 5 3
12 mos isoniazid given daily Placebo HIV-positive children 3 1
12 mos isoniazid given daily Placebo or no treatment HIV-negative adults and children 15 5
3 mos isoniazid plus rifapentine given once weekly Continuous isoniazid (up to 6 yrs) HIV-positive adults 1 1
2 mos rifampin and pyrazinamide given daily or  
twice weekly
6 mos isoniazid, 12 mos isoniazid HIV-positive adults and children 4 2
Abbreviation: GRADE = Grading of Recommendations Assessment, Development, and Evaluation. 
* Study details and information on evidence quality are available (Supplementary Tables; https://stacks.cdc.gov/view/cdc/84235).
TABLE 2. Network meta-analysis of regimens to treat latent tuberculosis infection
Risk and treatment
2017* 2018 update (unpublished) 
Odds ratio (95% credible interval) Odds ratio (95% credible interval)
Tuberculosis risk compared with no treatment
No treatment 1 (ref ) 1 (ref )
3 mos isoniazid plus rifapentine given once weekly 0.36 (0.18–0.73) 0.36 (0.18–0.72)
3–4 mos rifampin given daily 0.25 (0.11–0.57) 0.25 (0.12–0.50)
3 mos isoniazid plus rifampin given daily 0.33 (0.20–0.54) 0.33 (0.20–0.53)
6 mos isoniazid given daily 0.40 (0.26–0.60) 0.40 (0.26–0.59)
9 mos isoniazid given daily 0.46 (0.22–0.95) 0.47 (0.24–0.90)
Hepatotoxicity risk compared with no treatment
No treatment 1 (ref ) 1 (ref )
3 mos isoniazid plus rifapentine given once weekly 0.52 (0.13–2.15) 0.53 (0.13–2.13)
3–4 mos rifampin given daily 0.14 (0.02–0.81) 0.13 (<0.02–0.72)
3 mos isoniazid plus rifampin given daily 0.72 (0.21–2.37) 0.73 (0.22–2.38)
6 mos isoniazid given daily 1.10 (0.40–3.17) 1.11 (0.41–3.15)
9 mos isoniazid given daily 1.70 (0.35–8.05) 1.77 (0.35–8.32)
Abbreviation: ref = referent.
* The results from the 2017 analysis were published, citing all primary studies included in the analysis (Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. 
Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med 2017;167:248–55.); the 2018 update includes data subsequently 
published (Diallo T, Adjobimey M, Ruslami R, et al. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med 2018;379:454–63; Menzies D, 
Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med 2018;379:440–53).
adverse effects, a lower rate of hepatotoxicity, and a higher rate of 
treatment completion (13,14).
The potential disadvantages of the rifamycin-based regimens 
are the many drug interactions, including warfarin, oral 
contraceptives, azole antifungals, and HIV antiretroviral 
therapy (87). Rifabutin has fewer or less pronounced drug 
interactions and may be used in place of rifampin when 
rifampin is contraindicated due to drug-drug interactions 
and isoniazid cannot be used (87). Drug interactions with 
weekly rifapentine are fewer than with rifampin and appear 
to be fewer than with rifabutin; therefore, weekly isoniazid 
and rifapentine could be considered when rifampin is 
contraindicated, although clinical data are limited (88). Drug-
drug interactions between rifamycins and antiretroviral therapy 
are regularly updated by the U.S. Department of Health and 
Human Services (https://aidsinfo.nih.gov/guidelines/html/4/
adult-and-adolescent-opportunistic-infection/0). In HIV-
positive persons with low CD4+ lymphocyte counts, the risk 
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TABLE 3. Recommendations for regimens to treat latent tuberculosis infection
Priority rank* Regimen
Recommendation 
(strong or conditional)
Evidence 
(high, moderate, low, or very low)
Preferred 3 mos isoniazid plus rifapentine given once weekly Strong Moderate
Preferred 4 mos rifampin given daily Strong Moderate (HIV negative)†
Preferred 3 mos isoniazid plus rifampin given daily Conditional Very low (HIV negative)
Conditional Low (HIV positive)
Alternative 6 mos isoniazid given daily Strong§ Moderate (HIV negative)
Conditional Moderate (HIV positive)
Alternative 9 mos isoniazid given daily Conditional Moderate
Abbreviation: HIV = human immunodeficiency virus.
* Preferred: excellent tolerability and efficacy, shorter treatment duration, higher completion rates than longer regimens and therefore higher effectiveness; alternative: 
excellent efficacy but concerns regarding longer treatment duration, lower completion rates, and therefore lower effectiveness.
† No evidence reported in HIV-positive persons.
§ Strong recommendation for those persons unable to take a preferred regimen (e.g., due to drug intolerability or drug-drug interactions).
TABLE 4. Dosages for recommended latent tuberculosis infection treatment regimens
Drug Duration Dose and age group Frequency Total doses
Isoniazid* and rifapentine† 3 mos Adults and children aged ≥12 yrs Once weekly 12
Isoniazid: 15 mg/kg rounded up to the nearest 50 or 100 mg; 900 mg maximum
Rifapentine:
10–14.0 kg, 300 mg
14.1–25.0 kg, 450 mg
25.1–32.0 kg, 600 mg
32.1–49.9 kg, 750 mg
≥50.0 kg, 900 mg maximum
Children aged 2–11 yrs
Isoniazid*: 25 mg/kg; 900 mg maximum
Rifapentine†: see above
Rifampin¶ 4 mos Adults: 10 mg/kg Daily 120
Children: 15–20 mg/kg**
Maximum dose: 600 mg
Isoniazid* and rifampin¶ 3 mos Adults Daily 90
Isoniazid*: 5 mg/kg; 300 mg maximum
Rifampin¶: 10 mg/kg; 600 mg maximum
Children
Isoniazid*: 10–20 mg/kg††; 300 mg maximum
Rifampin¶: 15–20 mg/kg; 600 mg maximum
Isoniazid* 6 mos Adults: 5 mg/kg Daily 180
Children: 10–20 mg/kg††
Maximum dose: 300 mg
Adults:15 mg/kg Twice weekly§ 52
Children: 20–40 mg/kg††
Maximum dose: 900 mg
9 mos Adults: 5 mg/kg Daily 270
Children: 10–20 mg/kg††
Maximum dose: 300 mg
Adults: 15 mg/kg Twice weekly§ 76
Children: 20–40 mg/kg††
Maximum dose: 900 mg
 * Isoniazid is formulated as 100-mg and 300-mg tablets.
 † Rifapentine is formulated as 150-mg tablets in blister packs that should be kept sealed until use.
 § Intermittent regimens must be provided via directly observed therapy (i.e., a health care worker observes the ingestion of medication).
 ¶ Rifampin (rifampicin) is formulated as 150-mg and 300-mg capsules.
 ** The American Academy of Pediatrics acknowledges that some experts use rifampin at 20–30 mg/kg for the daily regimen when prescribing for infants and toddlers 
(Source: American Academy of Pediatrics. Tuberculosis. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2018 Report of the Committee on Infectious 
Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018:829–53).
 †† The American Academy of Pediatrics recommends an isoniazid dosage of 10–15 mg/kg for the daily regimen and 20–30 mg/kg for the twice-weekly regimen.  
for asymptomatic or subclinical TB disease increases, possibly 
facilitating rifampin resistance if TB disease is inadvertently 
treated with rifampin monotherapy (89).
Three Months of Daily Isoniazid Plus Rifampin
A regimen of 3 months of daily isoniazid plus rifampin is 
a preferred treatment that is conditionally recommended for 
adults and children of all ages and for HIV-positive persons as 
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drug interactions allow. HIV-negative adults and children with 
a positive tuberculin skin test (TST) who received 3 months 
of daily isoniazid plus rifampin appeared to have a similar risk 
for TB disease, hepatotoxicity, and adverse effects requiring 
discontinuation of therapy as those who received ≥6 months 
of isoniazid (23,35,44,51,90). Among children aged <15 years 
specifically, a 3-month course of daily isoniazid plus rifampin 
appeared as effective as a 6-month or longer course of isoniazid, 
because direct comparisons found no difference in TB disease 
and no differences in adverse effects requiring discontinuation 
of therapy or hepatotoxicity (67). In HIV-positive persons, no 
difference was found in the incidence of TB disease among 
those who received 3 months of daily isoniazid plus rifampin 
compared with those who received ≥6 months of isoniazid 
monotherapy, regardless of whether they were TST positive, 
TST negative, or anergic (34,46,63,72). Hepatotoxicity was 
less frequent among those receiving the shorter course of 
therapy, although discontinuation of therapy because of adverse 
effects was more frequent (63).
Potential drug interactions with rifampin and acquired drug 
resistance if TB disease is not adequately excluded also are 
important considerations (see previous section on 4 months 
of daily rifampin). In addition, hepatotoxicity risk might be 
greater with the two drugs given together than with either 
drug given alone (91).
Alternative Regimens: Six or Nine Months of  
Daily Isoniazid
Regimens of 6 or 9 months of daily isoniazid are alternative 
recommended regimens; 6 months daily is strongly 
recommended for HIV-negative adults and children of all 
ages and conditionally for HIV-positive adults and children 
of all ages and 9 months daily is conditionally recommended 
for adults and children of all ages, both HIV-negative and 
HIV-positive. Isoniazid reduces the risk for developing TB 
disease in persons with a positive TST, including HIV-negative 
adults and children (7,23,28,43,47,73), HIV-positive adults 
(27,38,42,46,60,72), and presumably also HIV-positive 
children. The drug can cause hepatotoxicity and be associated 
with discontinuation because of adverse effects, although these 
effects are more common in adults than children (23,43).
In HIV-positive persons who have a negative TST, anergy, 
or an unknown TST, the benefit of isoniazid is uncertain in 
settings with low TB incidence (38). For these HIV-positive 
persons, the potential exists for a reduction in the incidence 
of TB disease and an increase in adverse effects with isoniazid 
therapy; however, the likelihood of these effects remains 
uncertain because of wide confidence intervals resulting from 
too few events.
The evidence synthesis included multiple durations of 
isoniazid therapy in persons with a positive TST (3, 6, and 
12 months in HIV-negative persons and 6 months in HIV-
positive persons) (7,72). Among HIV-negative persons with 
inactive TB (defined as the presence of tuberculin positivity, 
stable fibrotic lung lesions, and negative sputum cultures in 
persons not previously treated), 6 and 12 months of therapy 
were more effective than 3 months of therapy, demonstrating 
the benefit of LTBI treatment with isoniazid in this high-risk 
subset of patients with LTBI (7). Studies of other regimens 
have persons with LTBI and fibrotic lesions but in much 
smaller numbers (14,68). According to the results of the 
systematic review process, among HIV-positive persons, 6 
months of therapy was highly effective (72), and the effect of 
other durations was unknown. Also reviewed was an analysis 
that included different, fewer trials than included in this 
report and found that 9 months of daily isoniazid therapy 
was perhaps more effective than 6 months and similar to 
12 months (25,92–94). However, no clinical trial data were 
available directly comparing 9 months of isoniazid to placebo, 
6 months of isoniazid, or 12 months of isoniazid.
Among HIV-positive persons living in areas with a high TB 
incidence, isoniazid is complementary to antiretroviral therapy 
in preventing TB disease. Two randomized controlled trials 
have demonstrated that isoniazid plus antiretroviral therapy 
decreased the incidence of TB disease to a greater extent than 
either isoniazid alone or antiretroviral therapy alone (27,61). 
Potential disadvantages of the regimen include its long 
duration, hepatoxicity, and low treatment completion rates 
(primarily due to the first two factors).
Discussion
A systematic literature review was performed of clinical trial 
data pertaining to effectiveness and toxicity of treatment of 
LTBI, including studies published since the 2018 World Health 
Organization LTBI guidelines (95). Evidence quality was 
evaluated using the GRADE approach, and a network meta-
analysis was performed, updated to include data from studies 
published since a previous network meta-analysis (10), to 
compare regimens not evaluated head-to-head in clinical trials. 
Recommendations were formulated on the basis of the balance 
of desirable and undesirable consequences of the intervention, 
the quality of evidence, patient values and preferences, and 
feasibility. These factors also informed the priority rank of 
the regimens as preferred or alternative, with preference for 
shorter regimens, given their similar efficacy compared with 
6–9 months of isoniazid but favorable tolerability and higher 
treatment completion rates. This combination of characteristics 
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should result in greater effectiveness of the shorter regimens in 
clinical settings. More effective treatment of LTBI will facilitate 
TB elimination (96). Prescribing providers or pharmacists who 
are unfamiliar with rifampin and rifapentine might confuse the 
two drugs. They are not interchangeable, and caution should 
be taken to ensure that patients receive the correct medication 
for the intended regimen.
Although 9 months of isoniazid was a preferred regimen 
in the guidelines published in 2000, both 6 and 9 months of 
isoniazid were recommended at that time (8). In these current 
guidelines, application of GRADE criteria resulted in a strong 
recommendation for 6 months of isoniazid as an alternative 
for those persons unable to take a shorter preferred regimen 
(e.g., due to drug intolerability or drug-drug interactions), 
particularly in HIV-negative persons. The longer duration 
of isoniazid could increase the risk for hepatotoxicity and 
although increased effectiveness is plausible, the two treatment 
durations have not been directly compared.
Two months of rifampin plus pyrazinamide are not 
recommended for treatment of LTBI because of the 
hepatotoxicity risk. However, in persons treated empirically 
for TB disease with isoniazid, rifampin, and pyrazinamide for 
2 months, this regimen will effectively treat LTBI in persons 
subsequently determined to have LTBI rather than TB disease.
Other Considerations
Following are several considerations for the use of these 
guidelines. First, the committee did not include cost-
effectiveness in evaluating the evidence; recommendations 
were based on evaluating effectiveness and toxicity of the 
regimens. Second, the committee did not evaluate evidence 
regarding how to implement these regimens programmatically 
(e.g., who to test and treat and management of side effects). 
Third, these guidelines focus on treatment regimens for persons 
with LTBI living in countries with low TB disease incidence. 
These guidelines do not address other empiric TB prevention 
strategies (e.g., 1 month of isoniazid plus rifapentine among 
HIV-positive persons living in settings with a high TB 
incidence regardless of results from the TST or an interferon-
gamma release assay) (97). Finally, shorter regimens should not 
be used for patients in whom rifamycins are contraindicated, 
including those taking medications with significant drug-drug 
interactions with rifamycins.
Conclusion
For patients without drug intolerability or drug-drug 
interactions, short-course (3–4 months) rifamycin-based 
treatment regimens are preferred over the longer-course 
(6–9 months) isoniazid monotherapy for treatment of LTBI. 
These guidelines can be used by clinicians, public health 
officials, policymakers, health care organizations, and other 
state and local stakeholders who might need to adapt these 
guidelines for individual clinical circumstances. Local and 
state TB programs in the United States answer questions about 
diagnosing and treating persons with LTBI in their jurisdictions 
(http://www.tbcontrollers.org).
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